In a placebo-controlled and randomized study, 285 dogs were enrolled to evaluate the effectiveness of Galliprant in the treatment of osteoarthritis pain.
Galliprant was prescribed to dogs ranging in age from 2 to 16.75 years old, weighing 9 to 131 pounds, with radiographic and clinical signs of OA. Galliprant was dosed at 2 mg/kg once daily for 28 days, alongside a vehicle-controlled group.
Dogs were assessed for improvements in pain and function by their owners, using the Canine Brief Pain Inventory (CBPI) scoring system on days 0, 7, 14, 21 and 28. A veterinary assessment also occurred at screening and on days 14 and 28.
For evaluation of improvement in chronic pain, pet owner assessments are critical to detect improvements in mobility and pain in the home environment. The CBPI is a validated questionnaire that asks dogs owners four questions about the severity of pain evident in a dog (severity score), and six questions about how pain interferes with a dog’s activity level (interference score). The questionnaire also has one overall impression score and is useful in detecting changes in a dog’s condition that result from intervention (e.g. medication or surgery).